Is Roivant Sciences Ltd (ROIV) overvalued? · rev $29.1M
Roivant Sciences Ltd (ROIV) is a biotechnology company listed on US.
This page asks whether Roivant Sciences Ltd (ROIV) looks expensive on cached numbers — not a short thesis.
Latest reported ROIV revenue for 2025-03-31 was $29.1M. Net income was -$356.7M. Revenue was down 11.2% from 2024-03-31 to 2025-03-31. ROIV currently screens at market cap $7.47B.
ROIV currently screens at market cap $7.47B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ROIV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ROIV stock page for the full model, not this heading.
Not investment advice.